RSV/hMPV Vaccine for Respiratory Infections

Recruiting at 12 trial locations

Overseen ByTrial Transparency email recommended (Toll free for US & Canada)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Sanofi Pasteur, a Sanofi Company

Trial Summary

What is the purpose of this trial?

This trial is testing a new vaccine for lung infections caused by RSV and hMPV in adults aged 60 and older. The vaccine aims to help the immune system recognize and fight these viruses.

Eligibility Criteria

Adults aged 60 or older can join this vaccine study if they're not pregnant, breastfeeding, and don't have a history of severe allergies to the vaccine's ingredients. They should be generally healthy or have stable chronic diseases. People with recent serious infections, heart inflammation history, bleeding disorders, or on certain medications may not qualify.

Inclusion Criteria

I am not pregnant, breastfeeding, and cannot become pregnant.

My doctor agrees I am fit for the trial and my condition has been stable without major treatment changes for 6 weeks.

I am 60 years old or older.

Exclusion Criteria

Participation at the time of study enrollment (or in the 4 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure

I have a weak immune system or I am taking medication that weakens my immune system, but I am stable if I have HIV.

I have not had COVID-19 or its symptoms in the last 10 days.

See 13 more

Treatment Details

Interventions

RSV/hMPV vaccine candidate (Cancer Vaccine)

Trial OverviewThe trial is testing different doses of an RSV/hMPV vaccine candidate in seniors to see how safe it is and how well it works (immunogenicity). Participants will get one shot and some will receive a booster after 12 months. A placebo group is included for comparison.

Participant Groups

9Treatment groups

Experimental Treatment

Placebo Group

Group I: Sentinel Cohort: RSV/hMPV Group 2 (Dose B)Experimental Treatment1 Intervention